Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 92.3% in September

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,500 shares, an increase of 92.3% from the September 15th total of 1,300 shares. Based on an average daily volume of 9,100 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 9,100 shares, the short-interest ratio is presently 0.3 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Adlai Nortye currently has a consensus rating of “Reduce” and an average price target of $9.00.

Adlai Nortye Stock Performance

Shares of Adlai Nortye stock opened at $1.66 on Wednesday. The firm has a fifty day moving average of $1.72 and a two-hundred day moving average of $1.71. Adlai Nortye has a one year low of $1.10 and a one year high of $3.89.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.